Compare Biogen Inc (BIIB) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs LyondellBasell Industries NV — how do they compare? Biogen Inc trades at $206.6 (market cap $30.13B), while LyondellBasell Industries NV trades at $63 (market cap $20.67B). The key difference: Biogen Inc is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LYB | |
|---|---|---|
Market Cap | $30.13B | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $82.38 |
52-Week Low | $128.93 | $42.28 |
Enterprise Value | $37.20B | $32.26B |
Dividend Yield | — | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
LYB trades at $62.97, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $70.56. Recent Q2 2026 earnings of $4.30 per share beat estimates, driven by improved margins from supply disruptions and cost cuts. However, 2025 fundamentals show declining revenue to $30.15B and a net loss of $745M, though cash flow remains positive. The stock is near its 52-week high of $83.94, reflecting optimism around operational improvements.
Outlook: Near-term upside exists from earnings momentum and favorable supply dynamics, but risks include volatile chemical margins and high debt. Analyst sentiment is mixed with 46% buy ratings, suggesting cautious optimism amid cyclical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
